期刊
ANTICANCER RESEARCH
卷 41, 期 2, 页码 1055-1062出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14862
关键词
Salvage therapy; chemotherapy; colorectal cancer; cohort study
类别
This study showed that chemotherapy after regorafenib or TFTD was associated with prolonged overall survival in advanced CRC patients. Further research is needed to determine the appropriate treatment choice for these patients.
Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据